Prostate cancer imaging and diagnosis: A pictorial review with common and uncommon findings

George Agrotis, Katerina Vassiou, Ioannis Tsougos, Anastasios Karatzas, Vasilis Tzortzis, Marianna Vlychou

Abstract


 

The implementation of multiparametric magnetic resonance imaging (mpMRI) is considered the standard of reference for the diagnosis, staging, and surveillance of prostate cancer. There has been an increase in the number of studies performed, and it is becoming more common for normal and incidental findings to be detected. Also, an inadequate description of cancerous findings may not prompt appropriate patient management, whereas over-reporting of normal findings comes with risks for the patient. This review article aims to improve awareness, and present key imaging features seen on prostate MRI, ranging from common to rare and from benign to cancer, also presenting the latest biopsy strategies for prostate cancer diagnosis.


Keywords


multiparametric magnetic resonance imaging, prostate, cancer

Full Text:

PDF

References


References

EAU-EANM-ESTRO-ESUR-ISUP_SIOG-Guidelines-on-Prostate-Cancer-2022_2022-04-25-063938_yfos.

Jason Oke. Prostate cancer now kills more people than breast cancer: cause for alarm? BMJ EBM Spotlight. 2018 Mar 8;

Drost FJH, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database of Systematic Reviews. 2019 Apr 25;

le Bihan D. The “wet mind”: Water and functional neuroimaging. Vol. 52, Physics in Medicine and Biology. 2007.

Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019 Sep;76(3):340–51.

Gundogdu E, Emekli E. Evaluation of prostate volume in mpMRI: comparison of the recommendations of PI-RADS v2 and PI-RADS v2.1. Diagnostic and Interventional Radiology. 2021 Jan 15;27(1):15–9.

Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol. 2004;6 Suppl 9(Suppl 9):S3–10.

Sarradin M, Lepiney C, Celhay O, Delpech PO, Charles T, Pillot P, et al. Évaluation prospective du délai minimum de réalisation de l’IRM prostatique après une biopsie de prostate : facteurs prédictifs cliniques et anatomopathologiques de remaniements hémorragiques. Progrès en Urologie. 2018 Feb;28(2):85–93.

Rosenkrantz AB, Taneja SS. Radiologist, Be Aware: Ten Pitfalls That Confound the Interpretation of Multiparametric Prostate MRI. American Journal of Roentgenology. 2014 Jan;202(1):109–20.

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, de Santis M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr;71(4):618–29.

Bjurlin MA, Carroll PR, Eggener S, Fulgham PF, Margolis DJ, Pinto PA, et al. Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. Journal of Urology. 2020 Apr;203(4):706–12.

Padhani AR, Weinreb J, Rosenkrantz AB, Villeirs G, Turkbey B, Barentsz J. Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. Eur Urol. 2019 Mar;75(3):385–96.

Thomas C. Perilesional sampling: the new standard for imaging-targeted prostate biopsies? Prostate Cancer and Prostatic Diseases. Springer Nature; 2023.

Bittencourt LK, Guricova K, Zucker I, Durieux JC, Schoots IG. Risk-based MRI-directed diagnostic pathway outperforms non-risk-based pathways in suspected prostate cancer biopsy-naïve men: a large cohort validation study. Eur Radiol. 2022 Apr 14;32(4):2330–9.

Barkovich EJ, Shankar PR, Westphalen AC. A Systematic Review of the Existing Prostate Imaging Reporting and Data System Version 2 (PI-RADSv2) Literature and Subset Meta-Analysis of PI-RADSv2 Categories Stratified by Gleason Scores. American Journal of Roentgenology. 2019 Apr;212(4):847–54.

Moldovan PC, van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, et al. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol. 2017 Aug;72(2):250–66.

Drost FH, Osses DF, Nieboer D. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 4:CD012663.

Brisbane WG, Priester AM, Ballon J, Kwan L, Delfin MK, Felker ER, et al. Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling. Eur Urol. 2022 Sep;82(3):303–10.

Halstuch D, Baniel J, Lifshitz D, Sela S, Ber Y, Margel D. Characterizing the learning curve of MRI-US fusion prostate biopsies. Prostate Cancer Prostatic Dis. 2019 Dec 1;22(4):546–51.

Halstuch D, Baniel J, Lifshitz D, Sela S, Ber Y, Margel D. Assessment of Needle Tip Deflection During Transrectal Guided Prostate Biopsy: Implications for Targeted Biopsies. J Endourol. 32:252–6.

Cornud F, Roumiguie M, Longchamps N. Precision Matters in MR Imaging-targeted Prostate Biopsies: Evidence from a Prospective Study of Cognitive and Elastic Fusion Registration Transrectal Biopsies. Radiology. 287:534–42.




DOI: http://dx.doi.org/10.36162/hjr.v8i2.541

Refbacks

  • There are currently no refbacks.